Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brown-Forman Corporation Class B (BF.B) vs Moderna, Inc. (MRNA) Price & Performance

Brown-Forman Corporation Class BTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Brown-Forman Corporation Class B vs Moderna, Inc. — how do they compare? Brown-Forman Corporation Class B trades at $28.01, while Moderna, Inc. trades at $60.61 (market cap $23.88B). Which is the better fit depends on your goals.

BF.BMRNA
Sector
Consumer StaplesHealth
52-Week High
$31.26$81.80
52-Week Low
$22.80$22.36
Market Cap
$23.88B
Enterprise Value
$20.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brown-Forman Corporation Class B

BF.B trades at $28.52, up 0.88% today, with a bullish technical signal from moving averages and strong trend strength (ADX). Earnings have beaten estimates in three of the last four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 forecast. The stock faces mixed analyst sentiment but shows consistent fundamental performance.

The outlook is cautiously optimistic given recent earnings strength, though limited analyst coverage and mixed ratings suggest uncertainty. Key risks include execution challenges and market volatility. Upside potential hinges on sustained earnings growth and broader market conditions.

Moderna, Inc.

Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.

The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Brown-Forman Corporation Class B

Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.

Read more on BF.B

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA